company background image
IRWD

Ironwood Pharmaceuticals NasdaqGS:IRWD Stock Report

Last Price

US$11.91

Market Cap

US$1.8b

7D

-1.7%

1Y

4.1%

Updated

07 Dec, 2022

Data

Company Financials +
IRWD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

IRWD Stock Overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.

Ironwood Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ironwood Pharmaceuticals
Historical stock prices
Current Share PriceUS$11.91
52 Week HighUS$12.95
52 Week LowUS$9.73
Beta0.96
1 Month Change1.28%
3 Month Change8.57%
1 Year Change4.11%
3 Year Change-3.87%
5 Year Change-23.41%
Change since IPO2.23%

Recent News & Updates

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

Recent updates

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Jul 21
Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Jun 22
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking

Mar 25
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 04
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price Returns

Feb 06
A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price Returns

Shareholder Returns

IRWDUS BiotechsUS Market
7D-1.7%-0.3%-3.7%
1Y4.1%-11.2%-21.2%

Return vs Industry: IRWD exceeded the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: IRWD exceeded the US Market which returned -20.6% over the past year.

Price Volatility

Is IRWD's price volatile compared to industry and market?
IRWD volatility
IRWD Average Weekly Movement3.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: IRWD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: IRWD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998219Tom McCourthttps://www.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis.

Ironwood Pharmaceuticals, Inc. Fundamentals Summary

How do Ironwood Pharmaceuticals's earnings and revenue compare to its market cap?
IRWD fundamental statistics
Market CapUS$1.83b
Earnings (TTM)US$167.57m
Revenue (TTM)US$420.53m

10.9x

P/E Ratio

4.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IRWD income statement (TTM)
RevenueUS$420.53m
Cost of RevenueUS$70.38m
Gross ProfitUS$350.15m
Other ExpensesUS$182.58m
EarningsUS$167.57m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.09
Gross Margin83.26%
Net Profit Margin39.85%
Debt/Equity Ratio67.0%

How did IRWD perform over the long term?

See historical performance and comparison